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DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle
Baolei Yuan,a Xingshun Wang,a Chunyan Fan,a Jin You,a Yuchu Liu,a Jason D. Weber,b Hanbing Zhong,a Yandong Zhanga
Department of Biology, Southern University of Science and Technology, Shenzhen, Chinaa; ICCE Institute, Department of Internal Medicine, Division of Molecular
Oncology, Washington University School of Medicine, Saint Louis, Missouri, USAb
The RNA helicase DHX33 has been shown to be a critical regulator of cell proliferation and growth. However, the underlying
mechanisms behind DHX33 function remain incompletely understood.We present original evidence in multiple cell lines that
DHX33 transcriptionally controls the expression of genes involved in the cell cycle, notably cyclin, E2F1, cell division cycle
(CDC), andminichromosomemaintenance (MCM) genes. DHX33 physically associates with the promoters of these genes and
controls the loading of active RNA polymerase II onto these promoters. DHX33 deficiency abrogates cell cycle progression and
DNA replication and leads to cell apoptosis. In zebrafish, CRISPR-mediated knockout of DHX33 results in downregulation of
cyclin A2, cyclin B2, cyclin D1, cyclin E2, cdc6, cdc20, E2F1, andMCM complexes in DHX33 knockout embryos. Additionally, we
found the overexpression of DHX33 in a subset of non-small-cell lung cancers and in Ras-mutated human lung cancer cell lines.
Forced reduction of DHX33 in these cancer cells abolished tumor formation in vivo. Our study demonstrates for the first time
that DHX33 acts as a direct transcriptional regulator to promote cell cycle progression and plays an important role in driving cell
proliferation during both embryo development and tumorigenesis.
DHX33 belongs to a family of DEAD/DEAH box RNA heli-cases, characterized by multiple conserved peptide motifs in
their primary amino acid sequences, that are important for sub-
strate binding and ATP hydrolysis. RNA helicases can couple ATP
hydrolysis with the conformational change of RNP complexes to
influence diverse activities of RNA, such as ribosome biogenesis,
microRNA (miRNA) biogenesis, transcription, splicing, transla-
tion, and mRNA decay (1, 2).
In previous studies, we identified DHX33 to be a significant
player in ribosome RNA synthesis and mRNA translation (3, 4).
Other research groups have found DHX33 to be important in
innate immunity as it can sense double-stranded RNA (dsRNA)
from pathogens (5, 6). Despite this earlier work, the detailed
molecular mechanisms of how DHX33 promotes numerous
cellular processes, such as cell proliferation, remain poorly de-
fined.We have identifiedDHX33 as a downstream transcriptional
and translational target of Ras that is sensitive to signals emanat-
ing from the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR
pathway (7). As the Ras gene has a mutation rate of 35% in non-
small-cell lung cancer (NSCLC), we sought to use established lung
cancers as a model for dysregulation of endogenous DHX33 ex-
pression.
Lung cancer can be divided into two major categories: small-
cell lung cancer comprising 20% and NSCLC comprising 80% of
all cases (8). Comprehensive cancer genome sequencing has
found both genetic and epigenetic alterations tightly correlated
with non-small-cell lung cancer development (9, 10). Among
these genetic alterations, mutations of cancer-critical genes have
been frequently detected in NSCLC; these include epidermal
growth factor receptor (EGFR), Ras, anaplastic lymphoma kinase
(ALK), and p53 genes (9–12). Two prominent drug targets are
ALK and EGFR, whose inhibitors have been widely used to treat
patients (12, 13). A recent report showed that activation of the Ras
signaling pathway accounts for more than 70% of all cases of
NSCLC (9). However, no efficient therapy for Ras-mutated can-
cers has been developed, and it is well known that Ras protein is a
notoriously difficult molecular target in the clinic (14). As such, it
is important that we identify other critical targets that reside
downstream of Ras.
In this report, we found that DHX33 promotes cell prolifera-
tion by transcriptionally regulating genes that control cell cycle
progression. DHX33 expression is required for continued cell
proliferation as it promotes cell cycle progression at the G1/S,
G2/M, and metaphase-anaphase transitions. DHX33 physically
associates with the promoters of numerous cell cycle genes where
it acts to recruit active RNA polymerase II (Pol II) loading.
To confirm established cell line data, we used a zebrafishmodel
system to study the role ofDHX33 during embryo development in
vivo. DHX33 gene knockout results in severe brain, eye, and liver
developmental defects. DHX33 knockout caused downregulation
of critical genes involved in cell cycle control, especially the cyclin
A2, cyclin B2, cyclin D1, cyclin E2, E2F1, cdc6, cdc20, and
minichromosome maintenance (MCM) complex genes.
We further used a lung cancer tissue microarray to evaluate
DHX33 protein levels in human normal lung tissues and malig-
nant tissues. We found DHX33 highly expressed in multiple lung
cancer samples as well as in numerous established lung cancer cell
lines. Acute depletion of DHX33 protein caused defects in cell
proliferation while also promoting apoptosis. Cancer cells with
reduced DHX33 levels were unable to form tumors in xenograft
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models, implicating DHX33 as a potential new therapeutic drug
target in treating NSCLC patients with a mutated Ras.
MATERIALS AND METHODS
Cell culture.H1299, Calu-1, Hcc827, and SK-LU-1 lung cancer cell lines
were maintained in RPMI 1640 medium containing 10% fetal bovine
serum (FBS), 2 mM L-glutamine, and streptomycin-penicillin. HeLa and
BeaS2B cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% FBS and streptomycin-penicillin. HEK293T
cells were maintained in DMEM with 10% FBS and streptomycin-peni-
cillin.
Lentivirus production. The targeting sequences of short hairpin
RNAs (shRNAs) for humanDHX33 are as follows (5= to 3=): 1-shDHX33,
CTCGGGAAACTTCCTCTGAAA; 2-shDHX33, GCTATCGCAAAGTG
ATCATTT; 3-shDHX33, CATTTCCTTTAGAACCCAAAT. A pLKO.1
vector encoding an shRNA for a scrambled sequence (shSCR) was
purchased from Addgene. To produce knockdown virus, 293T cells
were transfected by pLKO.1-shRNA, pCMV-VSV-G (where CMV is
cytomegalovirus and VSV-G is vesicular stomatitis virus G protein),
and pHR8.2R using Lipofectamine 2000 (Life Technologies) for virus
packaging. To produce DHX33-overexpressing virus, 293T cells were
transfected by pLVX-FLAG-DHX33, pCMV-VSV-G, and pHR8.2R us-
ing Lipofectamine 2000 (Life Technologies) for virus packaging. Culture
supernatants were harvested at 24 h and 48 h after transfection and then
centrifuged at 2,000 rpm for 5 min.
Plasmids. The following primers were used to clone the promoter of
human E2F1 gene into the NheI/XhoI site of the pGL3-control vector:
forward primer, 5=-CAAATCGGCTAGCCGGGCTCAAGCAATCCTC-3=;
reverse primer, 5=-AATTCCCTCGAGGGTCCCGGCCACTTTTACGC-3=.
The following primers were used to clone the promoter of human cdc6 gene
into theNheI/XhoI site of the pGL3-control vector: forward primer, 5=-CAA
ATCGGCTAGCCGCACAGCCCCTGGCATAC-3=; reverse primer, 5=-AAT
TCCCTCGAGGGCGAATGGCCACAGCGTTC-3=.
Immunoblotting. Whole-cell lysates were prepared by incubation
with whole-cell lysis buffer that included 0.5% NP-40 and 1% SDS sup-
plemented with Halt protease and phosphatase inhibitors (Sigma). Ly-
sates were cleared by centrifugation, and the protein concentration was
tested by a detergent-compatible (DC) assay (Bio-Rad). Lysates were
boiled with SDS sample buffer, separated by SDS-PAGE, and transferred
to polyvinylidene difluoride membrane (Millipore). Membranes were
blocked in 5% nonfat dry milk and Tris-buffered saline plus Tween
([TBS-T] 10 mmol/liter Tris-HCl [pH 7.4], 150 mmol/liter NaCl, 0.1%
Tween 20) buffer and incubated with primary antibodies diluted in
blocking buffer at 4°C overnight. Blots were washed with TBS-T buffer
and incubated with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (1:10,000; GE Healthcare) in blocking buffer at
room temperature. Immune complexes were visualized with an en-
hanced chemiluminescence kit (GE Healthcare). Primary antibodies
for immunodetection were the following (source): antitubulin (goat;
Santa Cruz), anti-DHX33 (Novus), anti-glyceraldehyde-3-phosphate de-
hydrogenase (anti-GAPDH; Bethyl), anticyclins (Santa Cruz), anti-E2F1
(Santa Cruz), and anti-MCM complexes (Abcam and Santa Cruz).
RNA sequencing. H1299 cells were infected by lentivirus encoding
shSCR or 2-shDHX33. Three days after lentiviral infection, cells were
harvested, and total RNA was extracted by Nucleospin RNA II kits. RNA
samples were then further purified with magnetic oligo(dT) beads after
denaturation. PurifiedmRNA samples were reverse transcribed into first-
strand cDNA, and a second cDNA was further synthesized. Fragmented
DNA samples were blunt ended and adenylated at the 3= ends. Adaptors
were ligated to construct a library. DNA was quantified by Qubit (Invit-
rogen). After cBot cluster generation, DNA samples were then sequenced
by an IlluminaHiSeq 2500 SBS instrument fromGenergy Bio (Shanghai).
Raw data were converted into Fastq format. The number of transcripts in
each samplewas calculated based on the number of fragments per kilobase
of transcript per million fragments mapped (FPKM); Cuffnorm software
was used to calculate the FPKMvalue for each sample, and the values were
log2 transformed. Cuffdiff software was used to calculate the differential
gene transcripts between different samples. For KEGG pathway analysis,
the entire set of transcripts was used as the background list, the differential
transcripts were used as the candidate list, and P was calculated. Signifi-
cant genes were categorized based on gene functions.
Chromatin immunoprecipitation (ChIP). After cells were trypsinized
and resuspended in completemedium, formaldehyde was added to a final
concentration of 1% to cross-link DNA and its interacting proteins; this
stepwas performed at room temperature for 10minwith a shaker. To stop
cross-linking, 1.25M L-glycine was added to a final concentration of 0.125
M; themixturewas shaken at room temperature for 5min. After cells were
washed with 1 phosphate-buffered saline (PBS), they were then resus-
pended in lysis buffer containing 1% SDS, 10mMEDTA, and 50mMTris
(pH 8.1) with protease and phosphatase inhibitors. To shear chromatin,
cell lysates were sonicated extensively, centrifuged to pellet debris, and
then diluted in buffer containing 0.5% NP-40, 50 mM Tris (pH 7.5), and
150 mM NaCl at a 1:5 ratio. Cell lysates were precleared by incubation
with 2.5g of sheared salmon spermDNA and 50l of protein A/G beads
for 30 min at 4°C. Following incubation with 5 g of antibody overnight
at 4°C, 2.5 g of sheared salmon sperm DNA and 50 l of protein A/G
beads were added, and samples were further incubated for 1 h. The beads
were then washed twice in radioimmunoprecipitation assay (RIPA) buf-
fer, twice in RIPA buffer containing 500 mMNaCl, and once with buffer
containing 0.5% NP-40, 50 mM Tris (pH 7.5), and 150 mM NaCl. The
beads were then extracted three times with a solution containing 1% SDS
and 0.1MNaHCO3. To reverse the cross-linking, 6 MNaCl was added to
the pooled extraction samples to a final concentration of 0.3 M, and sam-
ples were heated at 65°C for 5 h. DNA fragments were extracted by use of
a Qiagen QuickSpin column and eluted. Quantitative PCR (qPCR) was
performed with these purified DNA samples.
Apoptosis analysis. Apoptosis assays were performed with a Vybrant
Apoptosis Kit 2 (Molecular Probes) according to the manufacturer’s pro-
tocol.
Soft-agar assay.A total of 1.0 104 cells weremixed in 4.0ml of 0.3%
agar–DMEM–10% FBS as the top agar and plated on 60-mm plates with
4.0 ml of 0.6% agar–DMEM–10% FBS as the base agar. Plates were incu-
bated at 37°C, checked every 3 days, and fed with 2.0 ml of 0.3% agar–
DMEM–10% FBS every week. Colonies were photographed and counted
2 to 3 weeks later.
Immunohistochemistry (IHC). Human tumor tissue microarrays
were purchased from US Biomax. This tissue microarray contained sam-
ples from 95 cases of lung cancer. A rabbit polyclonal anti-humanDHX33
antibody was used at 1:50. Tissue slides were deparaffinized in xylene and
rehydrated in a series of graded alcohols, and the antigen was retrieved in
Tris buffer (pH 9.0) using a steamer. The sections were then treated with
1% hydrogen peroxide in methanol for 30 min to exhaust endogenous
peroxidase activity. After a 1-h preincubation in 10% normal fetal bovine
serum to prevent nonspecific staining, the samples were incubated with
primary antibody at room temperature for 2 h. A standard protocol was
then followed based on a Dako EnVision kit using polymer to amplify
signals. Both immunoreactive intensity and the percentage of stained cells
in different areas of the same slide were analyzed according to criteria
described previously (15). DHX33 expression was scored as follows: 0, no
staining; 1, weak; 2, moderate; and 3, strong. Additional points were
scored as 1, 2, or 3 when the percentage of positive cells was less than 25%,
25% to 50%, or greater than 50%, respectively.
Bioluminescence imaging. Cells were plated in a six-well tissue dish
and transfected with a pGL3-control promoter expressing firefly lucifer-
ase (F-luc). Twenty-four hours later, the cells were replated in 96-well
plates, D-luciferin was added, and the plate was imaged with an IVIS-100
instrument. These cells were also harvested for total RNA extraction and
analyzed by reverse transcription-PCR (RT-PCR) for determination of
firefly luciferase (F-luc) transcript levels. To analyze firefly luciferase
mRNA levels, the following primers were used: forward primer, 5=-CCC
Yuan et al.
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FIG 1 DHX33 transcriptionally controls genes involved in the cell cycle. (A) H1299 lung cancer cells were either infected with shSCR or 2-shDHX33 lentivirus.
Four days post-lentiviral infection, cells were harvested.Whole-cell lysates were subjected toWestern blot analysis with anti-DHX33 and antitubulin antibodies.
(B) RNA sequencing was performed on the total RNA extracted. The heat map shows standardized expression levels for cell cycle genes. (C) Pathway analysis for
significantly changed genes in DHX33 knockdown cells is shown. (D) H1299 lung cancer cells were infected with two different shRNAs targeting DHX33, with
shSCR as a control. At 4 days post-lentiviral infection, cells were harvested. Total RNA was extracted and reverse transcribed into cDNA; qPCR was performed
on these cells with the indicated primers. Bars indicate standard deviations from three independent analyses. All show statistically significant changes compared
to levels in the scrambled control. *, P  0.05 (n  3). (E) Whole-cell lysates from H1299 cells after transduction by lentivirus encoding either shSCR or two
shRNAs targeting DHX33. Whole-cell extracts were subjected to Western blot analysis with anti-DHX33 and antitubulin antibodies. (F) BeaS2B cells were
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TGGTTCCTGGAACAATT-3=; reverse primer, 5=-GCAACCCCTTTTTG
GAAACG-3=.
Recombinant DHX33 protein purification. The open reading frame
of mouse DHX33 was cloned into the BamHI/HindIII sites in the
pET32M-3C vector. The following primers were used to amplify DHX33
PCR products: forward primer, 5=-ATTATAGGATCCATGCCGGAGGA
GGCGAGCCT-3=; reverse primer, 5=-ATAAATAAGCTTGTTTCTGGC
CGTTCTCAGCTT-3=. Overexpressed wild-type recombinant DHX33
with a thioredoxin (Trx) tag at its N terminus and a 6His tag at its C
terminus was affinity purified from Escherichia coli through an Ni-nitri-
lotriacetic acid column (Qiagen).
Electric mobility shift assay (EMSA). Promoter sequences were PCR
amplified and then enriched to obtain probes. To amply the mouse cyclin
B2 promoter, the following primers were used: forward primer, 5=-TGT
AAGGATGATGGACCAAGAGT-3=; reverse primer, 5=-TGGCAAGTGC
GGACGAG-3=. To amply themouse cdc20 promoter, the following prim-
ers were used: forward primer, 5=-GACCTGGATTCTTACCAACCTC-3=;
reverse primer, 5=-AGCTCTCCCGAACACAAAC-3=. These probe DNA
samples were biotin labeled according to the manufacturer’s instructions
(Invitrogen). Biotin-labeled promoter DNA samples were then incubated
with or without DHX33 protein in the presence or absence of unlabeled
probe according to a standard protocol. After incubation, DNA samples
were separated by polyacrylamide gels and then transferred to nylon
membrane. After UV cross-linking, streptavidin-HRP conjugates were
added to the membrane to facilitate the detection of the labeled probes.
Zebrafish strains. The wild-type Tübingen line was maintained in a
circulating aquaculture system according to the description in The Ze-
brafish Book (16). Embryos were incubated at 28.5°C and staged under
standard conditions (17).
Cas9/gRNA design. The Cas9 and guide RNA (gRNA) plasmids were
a generous gift from Bo Zhang of Perking University. These two plasmids
were described previously (18, 19). For gRNA vector construction, gRNA
oligonucleotides targeting the protein-encoding exon of the zebrafish
DHX33 gene (ENSDART00000156224) was selected using the ChopChop
CRISPR/gRNA algorithm (http://chopchop.cbu.uib.no/). The sequence
of target site is GGCCGCGCAGCGCAGACGCTTGG.
Whole-mount in situ hybridization. Digoxigenin-labeled antisense
RNA probes were generated in vitro by using the zebrafish cDNA as a
template with RNA polymerase (Promega, Madison, WI). Whole-mount
RNA in situ hybridizations were performed essentially as described before
(20).
Imaging. Pictures of zebrafish embryos were taken with an AxioIm-
ager A1 microscope and AxioCam digital camera (Zeiss, Oberkochen,
Germany) and edited with Photoshop, version 7.0.
In vitro synthesis of capped Cas9 mRNA and gRNA. The Cas9 plas-
mid was linearized by XbaI and used as the template for capped Cas9
mRNA synthesis with amMESSAGEmMACHINET7 kit (Ambion). This
transcribed Cas9 mRNA was purified using an RNeasy minikit (Qiagen).
For DHX33 target guide RNA synthesis, we used the primers T7-cr fwd
(5=-GAAATTAATACGACTCACTATA-3=) and Tracr rev (5=-AAAAAAA
GCACCGACTCGGTGCCAC-3=) for the generation of the DNA tem-
plates of gRNA by PCR. The gRNA was transcribed in vitro with a T7
MAXIscript kit (Ambion), purified with a mirVana miRNA isolation kit
(Ambion), and quantified by NanoDrop (Thermo). The size and qual-
ity of the resulting Cas9 mRNA and gRNA were confirmed by electro-
phoresis through a 2% agarose gel.
Microinjection of zebrafish embryos and efficiency analysis. Cas9
mRNA (200 ng/l) and gRNA (25 ng/l) were coinjected into one-cell-
stage wild-type embryos, and the total volume was 3 nl. After microinjec-
tion, embryos were raised in E3 medium at 28.5°C for examination of
transduced with either shSCR or shDHX33 lentivirus. Four days after lentiviral infection, cells were extracted for total RNA. qPCR analysis was performed to
analyze the changes of the indicated cell cycle genes after normalization to GAPDHmRNA levels. Data were normalized to the level of the shSCR control. Data
represent the average of three independent experiments; bars indicate the standard deviations from three separate experiments. *, P 0.05 (n 3). (G) A similar
result was generatedwithCalu-1 lung cancer cells. Datawere normalized to the level of the shSCR control. *,P 0.05 (n 3). (H)H1299 cells after virus infection
were then pulsed by a uridine analog, 5-ethynyl uridine (EU), to label endogenous RNAs, followed by purification of labeled de novoRNAs by the use of a Click-iT
nascent RNA capture kit. Purified RNA was converted into cDNA, and then qPCR was performed on these samples by the designated primers. Bars indicate
standard deviations from three separate experiments. All showed statistically significant changes compared to control levels. *, P 0.05 (n 3).
TABLE 1 Primers for qPCR analysis for human genes
Human gene
product Primer Sequence (5=–3=)
hGAPDH Forward TGACAACGAATTTGGCTACA
Reverse GTGGTCCAGGGGTCTTACTC
DHX33 Forward CGTCCTCCACAACCCTCCTT
Reverse AAAATTCTCTTTGCACCAATCCTT
Cyclin A1 Forward ACACAGTTTCCCCTATGCTG
Reverse ATGCCTTCCGTGATGTCTG
Cyclin A2 Forward TCCATGTCAGTGCTGAGAGGC
Reverse GAAGGTCCATGAGACAAGGC
Cyclin B2 Forward AAAGTTGGCTCCAAAGGGTCCTT
Reverse GAAACTGGCTGAACCTGTAAAAAT
Cyclin D1 Forward AAGCTGTGCATCTACACCGA
Reverse CTTGAGCTTGTTCACCAGGA
Cyclin E2 Forward CTGCCTTGTGCCATTTTACC
Reverse GTCTTCAGCTTCACTGGACTAG
E2F1 Forward ACCTCTTCGACTGTGACTTTG
Reverse GAGCATCTCTGGAAACCCTG
CDC6 Forward TGGAAGCCTTTACCTTTCTGG
Reverse CCTCTTCCTGACAAATCTCCTG
CDC20 Forward GATGTAGAGGAAGCCAAGATCC
Reverse AAGGAATGTAACGGCAGGTC
CDC25c Forward CCACTCAGCTTACCACTTCTG
Reverse ACCATTCGGAGTGCTACAAAG
CDC26 Forward GGCCCTTAGTGTTGACTTCAG
Reverse CTCCTACAACTTCCACATCTTCC
MCM4 Forward TTCTTTGACCGTTACCCTGAC
Reverse GGGATGTCCTGATCACCATG
MCM6 Forward GTGATCAGGGATGTAGAACAGC
Reverse AGCTTGGGTCTCTTGAATACG
MCM7 Forward GATGCCACCTATACTTCTGCC
Reverse TCCTTTGACATCTCCATTAGCC
FEN1 Forward ACCCCGAACCAAGCTTTAG
Reverse CTCTTGATGTCATTCTCCCGG
Yuan et al.
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FIG 2 DHX33 promotes loading of active RNA polymerase II on cell cycle gene promoters and interacts with promoters of cell cycle genes. (A) H1299 lung
cancer cells were infected with three different shRNAs targeting DHX33, with shSCR as a control. At 4 days post-lentiviral infection, cells were harvested.
Whole-cell lysates were subjected toWestern blot analysis with the indicated antibodies. Fold changes in expression levels were calculated after quantitation with
ImageJ. (B) At 4 days after infection by lentivirus, the above-mentioned cells (shSCR, 2-sh-DHX33, and 3-shDHX33) were fixed by 1% formaldehyde, and then
subjected to ChIP analysis with anti-Pol II, anti-pPol II (phosphorylation on S2 of the CTD), with IgG as a control. Samples were then analyzed by PCR and
PAGE. A representative result is shown from three separate experiments. (C) H1299 cells were infected by lentivirus encoding either wild-type DHX33-FLAG or
an empty vector. Western blotting was performed on the above-mentioned cells with the indicated antibodies. (D) At 4 days post-lentiviral infection, cells were
cross-linked. Approximately equal amounts of sonicated cell lysates were used for total DNA extraction. The DNA samples were then analyzed by PCR, followed
by PAGE for input analysis for all the indicated genes. ChIP analysis was performed on the above-mentioned cells; antibodies used inChIP assays were anti-FLAG
and IgG. Purified DNA fragments were analyzed by PAGE following PCR with the primer sets in Table 2 to detect the association of DHX33 with certain gene
promoters. (E) Similar experiments were performed for analysis of DHX33 occupancy on the promoters of other genes. (F) H1299 cells were analyzed by ChIP
analysis with anti-DHX33 (Santa Cruz) or IgG as a negative control. PurifiedDNA fragments were analyzed by PAGE following PCRwith the primer sets in Table
2 to detect the association of DHX33 with the indicated gene promoters. IP, immunoprecipitation.
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phenotypes. The efficiency of the mutations induced by Cas9/gRNA was
evaluated by TA cloning and sequencing. Thirty embryos were collected
for genomic DNA extraction for PCR at 24 h postfertilization (hpf); the
PCR product was ligated with the pMD19-T vector (TaKaRa), and then
about 10 positive clones were selected randomly to extract plasmids for
sequencing. Primers used were the following: RV-M, AGCGGATAACA
ATTTCACACAGGA; forward primer, TATACAAACCAAATCTGAAA
CCC; reverse primer, TGCATACATCCTCTGTCAATAAA.
Quantitative PCR. The primers were purchased from Life Technolo-
gies. Total RNA was extracted by use of a NucleoSpin II (Clontech) RNA
isolation kit and reverse transcribed into cDNA by use of a SuperScript III
first-strand synthesis kit (Invitrogen). PCRs were performed with a Step
One Plus thermal cycler. SYBR green mix from Bio-Rad was used for all
quantitative real-time PCR (qRT-PCR) analyses. Transcript quantifica-
tion was calculated based on the CT (where CT is threshold cycle)
method after normalization to GAPDH values. Melt curve analysis con-
firmed that single products were amplified. Three separate experiments
were normally performed to obtain three sets of different RNA samples;
qPCR data presented were the average of three different times, and the
bars indicate the standard deviations (SD) calculated from these three
data sets.
Mouse xenograft model. Nude female mice were purchased from
Charles River Laboratories International, Inc., and received standard in-
stitutional care. They were at 5 weeks old at the time of surgery. For nude
mouse injection, lung cancer cells were infected as indicated in Fig. 7J.
Cells were trypsinized and resuspended in PBS at a concentration of 1
108 cells/ml. Five-week-old nude mice were injected subcutaneously with
1 107 cells along their flanks, with sample sizes of 5 mice per condition.
At 6 weeks postinfection, tumors were dissected, photographed, and
weighed. All mice were housed at the Southern University of Science and
Technology Laboratory Animal Center. The experiments were performed
by following standard protocols after approval by the university’s Labo-
ratory Animal Ethics Committee.
Statistical analysis.Data are presented as the means SD. Statistical
significance was determined using a Student t test, with a P value of0.05
considered significant.
RESULTS
DHX33 transcriptionally controls key genes involved in cell
cycle progression and DNA replication. To investigate the
mechanisms of how DHX33 promotes cell proliferation, we
first analyzed the genome-wide gene transcription of H1299
cells. We performed RNA sequencing after DHX33 knockdown
with scrambled knockdown sequences as a negative control (all
changes in gene transcription are shown in Table S1 in the
supplemental material). DHX33 knockdown efficiency is shown in
Fig. 1A. We observed a significant change for numerous genes
involved in cell cycle control following DHX33 knockdown (Fig.
1B). Pathway analysis indicated that the gene signature was most
strongly associated with cell cycle control and cell division (Fig.
1C). We validated the mRNA expression changes of many genes
by qRT-PCR, as shown in Fig. 1D. Twodifferent shRNAs targeting
the DHX33 gene were used, and the DHX33 knockdown effi-
ciency is shown in Fig. 1E. We performed multiple RT-PCR anal-
yses with two to three different shRNAs for DHX33 knockdown.
All results consistently indicated that mRNA levels of the indi-
cated genes (Fig. 1F and G) were significantly downregulated in
H1299 cells. The primer sequences are shown in Table 1. To eval-
uate whether this change would occur in other cell lines, we ana-
lyzed the transcription levels for these genes in Calu-1 and BeaS2B
cells after DHX33 knockdown. As shown in Fig. 1F andG,DHX33
knockdown also lowered the expression levels of key cell cycle
genes expressed in these cells, too. Changes in the mRNA steady-
state levels of the above-mentioned genes could be due to the
decrease in newly synthesizedmRNAs, or it could be due to accel-
erated mRNA decay. To study whether the reduction of the
mRNA levels was due to a decrease in mRNA synthesis, we pulse-
labeled endogenous RNAs for 30 min with the uridine analog,
5-ethynyl uridine (EU), followed by purification of labeled de
novo RNAs. As shown in Fig. 1H, we found that, compared to
level with the scrambled control, the levels of newly synthesized
mRNAs for these genes were decreased significantly.
DHX33 is required for active RNA polymerase II recruit-
ment to promoters of cell cycle genes. To investigate whether
DHX33 loss would result in a concomitant decrease in protein
levels for these cell cycle genes, we performed Western blot anal-
ysis with representative cell cycle proteins for H1299 cells that had
been transduced either with shSCR or with shRNAs targeting
DHX33. As shown in Fig. 2A, we found that DHX33 knockdown
caused a marked reduction of the cell cycle proteins: cdc6, cdc20,
cyclin A2, cyclin B2, cyclin E2, E2F1,MCM4,MCM6, andMCM7.
This occurred roughly in a dose-dependent manner correlating
with the degree of DHX33 knockdown efficiency, especially for
cdc6, cdc20, cyclin B2, cyclin E2,MCM4,MCM6, andMCM7.We
further studied the occupancy of RNA polymerase II and phos-
phorylated RNA polymerase II on the C-terminal domain (pS2-
CTD) required for gene expression at designated gene promoters.
With 2-shDHX33 and 3-shDHX33 targeting DHX33 in H1299
cells as shown in Fig. 2A, we found that DHX33 knockdown sig-
nificantly reduced the abundance of phosphorylated RNA poly-
merase II at the cell cycle gene promoters (Fig. 2B). Compared to
total RNA polymerase II, the occupancy of phosphorylated RNA
TABLE 2 Primers for ChIP analysis of human gene promoters
Gene promoter Primer Sequence (5=–3=)
Cyclin A2 promoter Forward CCTGCTCAGTTTCCTTTGGTTT
Reverse AGCGGCGGCTGTTCTTG
Cyclin B2 promoter Forward TTGGGAATACAATGGAGAACTTACA
Reverse TCCGGGTTGCTCAGGGAT
Cyclin D1 promoter Forward GAAGGCAGCCCGAAGAGTC
Reverse TCCAGCAGCAGCCCAAGAT
Cyclin E2 promoter Forward GTGGTGGCGATCTTTCTT
Reverse TCCCTTGCTTCCTCTCTT
E2F1 promoter Forward CGCCACTTCATCGTATTGTAAAC
Reverse ATCTCCAACAGCCAACGTATAG
CDC6 promoter Forward GGGGAACCACATCTTGACACTT
Reverse TGAGGCCACGACCACTGAA
CDC20 promoter Forward TCTTCCAGATAGGCAGGTTTGA
Reverse CCAGAGCTACTTAGGGTACATTCCA
MCM4 promoter Forward CCAGAACGACTCGGGAAGC
Reverse CCCTGGCCGGTCATCAA
MCM6 promoter Forward GTCAGCACCACCACAATAA
Reverse CGGAGTAAGACTCTATGGAAGA
MCM7 promoter Forward GTAGACAAGAAGACGGCGAAAGT
Reverse GGGCGTCGGAAGGGAAT
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Pol II demonstratedmore significant reduction inDHX33 knock-
down cells. As a negative control, we analyzed the occupancy for
RNA polymerase II on the ribosomal DNA (rDNA) promoter; we
did not observe the interaction between rDNAandRNApolymer-
ase II. However, when we analyzed the occupancy of RNA poly-
merase II on the GAPDH gene promoter, we found that the occu-
pancy of phosphorylatedRNApolymerase II wasmildly decreased
in 2-shDHX33 cells while the occupancy for the whole RNA poly-
merase II was kept almost the same. These results were consistent
with the requirement of DHX33 for expression of these genes and
indicated that DHX33 directly functions in transcriptional preini-
tiation complex assembly at their promoters.
DHX33 protein interacts with the promoters of genes in-
volved in the cell cycle.To studywhether the transcriptional con-
trol of cell cycle genes by DHX33 occurred directly or indirectly,
we sought to determine whether DHX33 physically associated
with these promoters. To observeDHX33 bound to these promot-
ers, we performed chromatin immunoprecipitation experiments
in H1299 cells. We first infected these cells with lentiviruses over-
expressing either wild-type FLAG-DHX33 or an empty vector
alone as a control. We checked the overexpression efficiency by
Western blotting, (Fig. 2C). After cells were cross-linked with 1%
formaldehyde and immunoprecipitated with anti-FLAG anti-
body (Fig. 2D and E), we discovered that DHX33 binds to the
FIG 3 DHX33 directly binds on the promoters of cell cycle genes through amino acids 480 to 580 and positively regulates gene transcription. (A) Diagrams of
the sequences of a panel of deletion mutants (D1 to D5 in the blot below) compared to the sequence of wild-type (WT) DHX33 are shown in the upper panel.
Helic C, helicase C; OB-NTP-bind, oligonucleotide/oligosaccharide-nucleoside triphosphate binding. The Western blot shows the expression of each protein
after immunoprecipitation (IP). Vec, vector. (B)H1299 cells were infected by lentivirus encoding eitherwild-typeDHX33-FLAGor each of the deletionmutants,
with an empty vector as a control. At 4 days post-lentiviral infections, cells were cross-linked. Approximately equal amounts of sonicated cell lysates were used
for ChIP analysis. Purified DNA fragments were analyzed by PAGE following PCR with the primer sets to detect the association of DHX33 with GAPDH and
cyclin B2 gene promoters. For GAPDH primers, we used GAPDH forward primer 5=-GCCACATCGCTCAGACACCAT-3= and GAPDH backward primer
5=-CCCATACGACTGCAAAGACCC-3=. (C) SDS-PAGE analysis for isolated recombinant DHX33 protein from E. coli. (D) EMSA for promoters of cyclin B2
and cdc20 with DHX33 recombinant protein. (E) Diagrams of promoter-reporter constructs for E2F1 and the cdc6 gene. (F) H1299 lung cancer cells were
infected with either shSCR or 2-shDHX33 lentivirus. At 2 days post-lentiviral infection, equal amounts of the promoter constructs were transfected into cells.
Promoter activities for E2F1 and cdc6 were detected 24 h later by analyzing F-luc activity. Data presented is the relative ratio of the F-luc activities in shSCR to
shDHX33 cells for each promoter-reporter plasmid. DNA transfection efficiency was normalized after quantitative PCR analysis. Experiments were repeated
three times. SV40, simian virus 40. *, P 0.05 (n 3).
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promoter region of many genes involved in the cell cycle and in
cell division, including the MCM4, MCM7, cdc6, cdc20, cyclin
A2, cyclin B2, cyclin D1, cyclin E2, and E2F1 genes. These
results provide evidence that DHX33 physically interacts with
these gene promoters and thereby directly promotes the load-
ing of active RNA polymerase II to initiate gene transcription.
Furthermore, we also performed chromatin immunoprecipita-
tion analysis for endogenous DHX33, and as shown in Fig. 2F,
endogenous DHX33 interacts with the promoters of this group of
genes. The primers for ChIP analysis are shown in Table 2.
DHX33 interacts with gene promoters through the domain
of residues 480 to 580. To further investigate which domain of
DHX33 is critical in binding to gene promoters, we performed
chromatin immunoprecipitation analysis with deletion mutants
ofDHX33 as shown in Fig. 3A andB.We found that the domain of
residues 480 to 580 is important in mediating the protein-DNA
interaction. To study whether the interaction between DHX33
and DNA is direct, we performed an EMSA (Fig. 3C and D). We
first isolated thioredoxin-tagged DHX33 from E. coli, and then
protein purity was checked by SDS-PAGE (Fig. 3C). After cells
FIG 4 Acute DHX33 knockdown leads to cancer cell cycle arrest and apoptosis. (A and B) H1299 or Calu-1 cells were transduced with either shSCR or
2-shDHX33 lentivirus. At 4 days postinfection, cells were subjected to cell cycle analysis by flow cytometry after staining with propidium iodide. Quantitation of
each cell cycle phase for both the scrambled control and DHX33 knockdown samples is shown. Experiments were repeated three times; a typical result is shown.
(C and D) H1299 cells or Calu-1 cells were transduced with either shSCR or 2-shDHX33 lentivirus. At 5 days postinfection, cells were subjected to apoptosis
analysis by flow cytometry with a Vybrant apoptosis kit after PI labeling of nuclei and fluorescein isothiocyanate labeling of annexin V. The percentage of cells
is shown in each quadrant. The number of apoptotic cells was calculated and graphed. Bars indicate standard deviations from three separate analyses.*, P 0.01
(n 3).
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were incubated with biotin-labeled cyclin B2 or cdc20 gene pro-
moters, we found a significant band shift, which was somehow
reversed by coincubation with a 2-fold amount of unlabeled
probes. To study whether the absence of DHX33 would de-
crease the promoter activity of the above-mentioned genes, we
cloned E2F1 and cdc6 proximal promoters (1 kb upstream of
start codon) into the pGL3-control plasmid. A schematic of
these plasmids is shown in Fig. 3E. After the constructs were
transfected into either control cells or DHX33 knockdown
cells, we found that the promoter activities for both E2F1 and
cdc6 were decreased (Fig. 3F).
DHX33 protein deficiency triggers cancer cell cycle arrest,
reduction in DNA replication, and apoptosis. We previously
found in wild-type mouse embryonic fibroblasts and primary hu-
man fibroblasts that DHX33 loss would cause cell cycle arrest at
the G1/S boundary in a p53-dependent manner (3). Here, in
H1299 cells that express mutant p53 and in Calu-1 cells that have
a p53 deletion, we analyzed whether DHX33 deficiency would
cause cell cycle arrest independent of p53 function. As shown in
Fig. 4A and B, loss of DHX33 caused a significant increase of
G1-phase cells and amarked reduction in S-phase cells, indicating
that cell cycle arrest in the G1/S-phase transition in lung cancer
FIG 5 DHX33 gene knockout causes severe developmental defects due to downregulation of cell cycle genes in zebrafish. (A) CRISPR/Cas9 gene targeting site
(black bar) on exon 3 of DHX33. Both forward and reverse primers are shown in the gene sequence for screening the mutant clones by PCR. (B) The sequencing
results for both the sibling and theDHX33mutants on exon 3. Highlighted are the 11 bpmissing in theDHX33mutants. (C) The 11-bp deletion causes a reading
frame shift, and the putative mutated DHX33 protein has a premature stop codon and becomes a truncated protein with 190 amino acids. (D) The expression
pattern of DHX33 in zebrafish. A whole-mount in situ hybridization was performed for zebrafish embryo development. The stages are labeled on the top right
corner of each frame. Before 24 hpf, DHX33 is expressed universally; after 24 hpf, expression is gradually restricted in neural tissue and digestive tissue. (E) A
DHX33 homozygousmutant at 96 hpf. Mutant embryos developmore slowly than those of siblings. Their heads and eyes aremuch smaller. Frames A to D show
side views; frames E and F are dorsal views. (F) ThemRNA levels of the indicated geneswere analyzed by qPCR. Embryoswere collected at 4 days postfertilization,
and total RNA was extracted. Bars indicate standard deviations from three separate experiments. *, P 0.05 (n 3).
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cells occurs independent of p53. To analyze whether DHX33 loss
would decrease DNA replication due to a reduction ofMCMpro-
teins, we analyzed the stability of an episomal plasmid in cancer
cells. The plasmid encodes both the EBNA1 gene and OriP, which
functions as aDNA replication of origin.OriP plasmids can link to
chromosomes duringmitosis and segregate to daughter cells with-
out integration into host chromosomes. As this plasmid contains
a hygromycin selection marker, cells can be selected by hygromy-
cin. We transfected this plasmid into both the scrambled and
DHX33 knockdown cells and then selected them in either puro-
mycin or hygromycin-puromycin medium. In contrast to results
with the shSCR control, we found thatDHX33 knockdown caused
decreased cell survival in this setting, indicating that DHX33 is
important in DNA replication (data not shown).
To evaluatewhether loss ofDHX33would lead to cell death, we
performed apoptosis assays by annexin V/propidium iodide (PI)
costaining. Annexin V-positive cells are early apoptotic cells while
annexin V/PI-double-positive cells are late apoptotic cells. By cal-
culating the cells in the upper right and lower right quadrants in
the graphs shown in Fig. 4C and D, we can evaluate the effect of
DHX33 loss on apoptosis in both H1299 and Calu-1 cells. Impor-
tantly, we found that in both cell types, acute depletion of DHX33
caused significant cell death through apoptosis, as shown in Fig.
4C and D. Six days after lentiviral infection, DHX33 knockdown
caused the apoptotic index to increase from 3% to approximately
12 to 20% compared to control levels.
DHX33 gene knockout causes severe developmental defects
and downregulation of cell cycle genes in zebrafish. To further
investigate whether DHX33 promotes gene transcription in vivo,
we chose zebrafish as a model system. The DHX33 homolog in
zebrafish has up to 71% sequence identity and 83% sequence sim-
ilarity with the humanDHX33 protein.We designed a guide RNA
to specifically target the third exon of the DHX33 homolog gene
and utilized CRISPR/Cas9 to edit the genome DNA sequence for
the DHX33 gene. We obtained a clone with a deletion of 11 bp in
exon 3. This deletion caused a frameshift in the open reading
frame, introduced a premature stop codon, and resulted in the
production of a truncated DHX33 without an RNA helicase core
domain (Fig. 5A to C). We also performed whole-mount RNA-
fluorescence in situhybridization (FISH) analysis forDHX33 gene
expression during the course of zebrafish embryo development.
We foundDHX33 to be a ubiquitous protein in embryos before 24
hpf (hours postfertilization) and gradually restricted to neural tis-
sue and the digestive tract (Fig. 5D). Heterozygotes for this
DHX33 mutant have no obvious phenotypes; they are fertile and
appear to be normal. For DHX33 homozygote mutants, until 48
hpf, the appearance of the mutant embryo was nearly normal.
After 48 hpf, the mutant embryo developed more slowly than
siblings. At 96 hpf, mutant embryos were smaller, especially head
and eyes, and had heart edema (Fig. 5E). Mutant embryos died
eventually.We purified the total RNA from thesemutant embryos
on day 3 postfertilization and analyzed the mRNA levels for genes
involved in the cell cycle. As shown in Fig. 5F, we found that all
previously analyzed cell cycle genes were significantly downregu-
lated in the mutants compared to the levels in the wild-type ze-
brafish. The primer sequences are shown in Table 3. This result
confirmed previous findings by providing the evidence in vivo.
DHX33 protein expression in non-small-cell lung cancers.
To study the possible role of DHX33 in cancers, Western blot
analysis was used to measure DHX33 protein expression in four
non-small-cell lung cancer cell lines; these results were then com-
pared to those in BeaS2B and HeLa cells, where we found DHX33
protein to be highly expressed. As shown in Fig. 6A, after normal-
ization by 	-tubulin protein levels, DHX33was found to be highly
expressed in three out of four non-small-cell lung cancer cell lines.
Two of these lines, H1299 and Calu-1, are K-Ras-mutated cancer
cell lines.We found that DHX33 protein levels correlated with the
doubling times (Fig. 6B). We observed only mild changes in the
mRNA levels of DHX33 in non-small-cell lung cancer tissues
compared to levels in normal samples using public Oncomine
data sets (Fig. 6C).We further performed immunohistochemistry
staining for DHX33 with a set of human non-small-cell lung can-
cer tissue arrays. Our results indicated that DHX33 was highly
expressed in 30% of the 95 lung cancer cases while normal lung
tissues all exhibited weak staining for DHX33. Images of all of the
DHX33-positive tumor tissues, the representative normal tissues,
and the negative tissues are shown in Fig. 6D and E. The detailed
tumor type, stages, and scores are summarized in Table 4. Statis-
tical analysis from IHC is shown in Table 5 and clearly shows that
DHX33 expression correlates with tumor stages and ages, imply-
ing that DHX33 may function to promote tumor formation. Ad-
ditionally, we performed another lung cancer tissue array with
TABLE 3 Primers for qPCR analysis of zebrafish genes
Zebrafish gene
product Primera Sequence(5=–3=)
GAPDH FP GCTTCTCACAAACGAGGACACA
RP GTCAAGAAAGCAGCACGGGT
DHX33 FP TGCCGCTCTACGCCTCACT
RP GCAATGTTGGTGGACAGAATCA
Cyclin A2 FP GCGGGAAATGGAGGTCAAG
RP TCCCACTTCCACCAACCAGT
Cyclin B2 FP CACAAACCAGTTCAGACAAAGAAGG
RP GCTGGACCTGGGCACTTTTG
Cyclin D1 FP GAACACTTCCTTGCCAAACTGC
RP GTCGGTGCTTTTCAGGTACAGTC
Cyclin E2 FP CCCGCAACACATTACAAGAAAG
RP TAAGACACTGGCACTAACATCACC
E2F1 FP GCAACGCCACATCATACAAGC
RP CGTAGCGGGATTTCTCCACA
MCM4 FP GAACGCTGGTCTGGATCTCAA
RP CGCTGTAGGGTCGCACTTG
MCM6 FP ACGAAGGTTTGCGTGGGC
RP CTGGTGCAGAGGTTATGGTAGAGG
MCM7 FP GGTTGTGCGTGATGTGAAGGC
RP ATGATGAGCGGCGTGAAGC
CDC6 FP GTGTTCCTCAAGTGGCTCGG
RP CTTCACACAGCTTGCCCAACT
CDC20 FP GCCCTCTACTGCGCCAAATC
RP ATAACCCTCTGGTGCGTAAAGC
a FP, forward primer; RP, reverse primer.
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FIG 6 Overexpression of DHX33 in Ras-mutated lung cancer cell lines and non-small-cell lung cancers. (A) A panel consisting of four different lung cancer cell
lines, the normal lung epithelial cell line BeaS2B, and HeLa cells was analyzed for DHX33 protein expression byWestern blotting. A total of 50 g of whole-cell
extracts was used for analysis. Tubulin was used as a loading control. Quantitation of the signal was made by ImageJ software and normalized by tubulin levels.
(B) Equal numbers of the indicated lung cancer cell lines were plated, and cells were counted on a daily basis. Doubling times were estimated based on the growth
curves. (C) Analysis of DHX33mRNA expression in non-small-cell lung cancers using the Oncomine database (36). Oncomine was searched for non-small-cell
lung cancer data sets in which DHX33 mRNA levels exhibited significant differences (t test, P value of0.001) in cancer versus normal tissue. The graphs show
box plots of a data set comparing the cancer and normal samples. The 25th to 75th percentiles are indicated by a filled box, with the median indicated by a
horizontal line, and the value of themedian is indicated on top; the number of each type of tissue sample is shown at the bottom. (D) Immunohistochemistry was
performed on a human tissue array, including samples from95 cases of various stages of non-small-cell lung cancers tissues and three normal lung tissue samples.
Brown indicates positive DHX33 expression; blue demarcates nuclei by eosin staining. All positive tissues are presented and are categorized into DHX33 strong,
DHX33medium, and DHX33 weak groups. All images were taken at a magnification of10. Data are summarized in Tables 4 and 5. (E) Representative images
at variousmagnifications to show positive and strong nucleus staining of DHX33. (F) Immunohistochemistry was performed on a human tissue array, including
45 pairs of malignant non-small-cell lung cancer tissue specimens, an adjacent normal specimen, and 10 normal tissue samples. Typical images of normal,
adjacent normal, and malignant lung cancer tissues are shown. All images were taken at a magnification of20. Arrows indicate punctate nucleolus staining.
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more normal tissue controls. This tissue array contained 45 sam-
ples of paired non-small-cell lung cancer tissue, adjacent normal
lung tissue, and 10 normal lung tissues. We found DHX33-posi-
tive nucleolus tissues in a substantial number of non-small-cell
lung cancer samples;DHX33was expressed in the nucleoli of 9 out
of 45 lung cancer tissues but not in the nucleoli of adjacent normal
lung tissues (Fig. 6F).
DHX33 promotes NSCLC cell proliferation and tumor de-
velopment in vitro and in vivo. To evaluate the consequences of
DHX33 depletion in lung cancer cells, we used small interfering
RNAs through lentivirus delivery to stably knock downDHX33 in
DHX33 highly expressing lung cancerH1299 andCalu-1 cells.We
then analyzed several cellular processes, including cell prolifera-
tion and anchorage-independent cell growth. As shown in Fig. 7A
and B, after DHX33 depletion, these cancer cells had lost many of
their proproliferative phenotypes. Thiswas observed in both long-
term focus formation and the short-term growth curve analysis
(Fig. 7A to C). When the cells transduced with the scrambled
control and the two shRNAs targetingDHX33were compared, we
found that 2-shDHX33 had better knockdown efficiency than
1-shDHX33, and, similarly, more impact on cell proliferation,
indicating a dose-dependent effect. The ability to grow in an an-
chorage-independent manner is a hallmark of cancer cells. We
performed this analysis in both H1299 and Calu-1 cells. DHX33
knockdown caused a significant reduction in soft-agar colo-
nies, as demonstrated in Fig. 7D and E. To further evaluate
whether DHX33 promotes lung cancer growth in vivo, we used
mouse xenograftmodels to study the effect ofDHX33 knockdown
on tumor growth. Two days after lentiviral infection of lung can-
TABLE 4 List of DHX33-positive lung cancer tissues with patient pathological data and IHC score
Sample no. Patient age (yr) Tumor type Stagea Scoreb
1 62 Squamous cell carcinoma T2N1M0 3
 2
2 60 Squamous cell carcinoma T3N3M0 3
 3
3 47 Bronchioloalveolar carcinoma T2N0M0 3
 3
4 77 Squamous cell carcinoma T2N1M0 3
 2
5 56 Squamous cell carcinoma T2N1M0 3
 2
6 56 Squamous cell carcinoma T2N0M0 2
 3
7 76 Squamous cell carcinoma T2N1M0 2
 3
8 53 Undifferentiated carcinoma T2N0M0 2
 2
9 51 Undifferentiated carcinoma T2N2M0 3
 3
10 55 Bronchioloalveolar carcinoma T2N0M0 3
 2
11 58 Adenosquamous carcinoma T2N0M0 3
 2
12 70 Adenocarcinoma T3N1M0 3
 2
13 73 Squamous cell carcinoma T2N0M0 2
 2
14 74 Bronchioloalveolar carcinoma T3N0M0 2
 2
15 66 Adenocarcinoma T2N0M0 2
 2
16 74 Bronchioloalveolar carcinoma T4N0M0 2
 2
17 50 Squamous cell carcinoma T2N0M0 2
 2
18 42 Bronchioloalveolar carcinoma T2N1M0 2
 2
19 75 Adenosquamous carcinoma T2N0M0 2
 2
20 40 Squamous cell carcinoma T2N1M0 1
 3
21 55 Undifferentiated carcinoma T2N0M0 1
 3
22 59 Adenosquamous carcinoma T4N1M0 2
 2
23 63 Adenosquamous carcinoma T2N1M0 2
 2
24 64 Bronchioloalveolar carcinoma T3N0M0 1
 3
25 65 Adenocarcinoma T2N1M0 2
 1
26 63 Small cell carcinoma T2N0M0 1
 3
27 70 Bronchioloalveolar carcinoma T3N1M0 1
 2
28 51 Adenosquamous carcinoma T3N1M0 2
 1
a Stages are indicated according to the generally accepted TNM (T, tumor; N, node; M, metastasis) system.
b The first number indicates the DHX33 expression level as follows: 0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining. The second score represents the
percentage of positive cells, scored as 1, 2, or 3 when the percentage of positive cells was less than 25%, 25% to 50%, or greater than 50%, respectively.
TABLE 5 Statistical summary of IHC staining results according to
tumor subtypes and stages
Parameter No. of positive tissues (%)
Tumor subtype
Squamous cell carcinoma 9/49 (18.4)
Adenocarcinoma 3/18 (16.7)
Bronchioloalveolar 7/11 (63.6)
Adenosquamous carcinoma 5/9 (55.6)
Undifferentiated carcinoma 3/5 (60)
Small-cell carcinoma 1/3 (33.3)
Tumor stage
I-II 20/74 (27)
III 6/17 (35)
IV 2/5 (40)
Patient age (yr)
50 3/19 (15.8)
50–60 11/50 (22)
60–70 8/20 (40)
70 6/13 (46.2)
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FIG 7 DHX33 promotesNSCLCproliferation and tumor development in vitro and in vivo. (A) Calu-1 andH1299 lung cancer cells were infectedwith either shSCR or
shDHX33 lentivirus.At 4dayspost-lentiviral infection, cellswereharvested.Whole-cell lysateswere subjected toWesternblot analysiswith anti-DHX33andantitubulin
antibodies. (B) At 3 days postinfection, cells were split, and approximately 5,000 cells per condition were plated on a 100-mm dish in triplicates. Cells were further
cultured for 2weeksuntil theywere subjected to focus analysis. Typical images for the cultureof the indicated transduced cells are shown. (C)The above-mentioned cells
were trypsinized; equal numbers of cells were plated onto six-well plates, and cells were counted on a daily basis. Bars indicate standard deviations from three separate
counts. (D)Calu-1 andH1299 cells were transducedwith either shSCRor shDHX33 lentivirus. Cells were then subjected to soft-agar analysis after andplated at 1 104
into each 60-mmdish. A typical image is shown after culturing for 2 weeks. (E) Quantitation of colony numbers in the soft-agar assay. Error bars were based on results
from triplicates. *, P 0.05 (n 3). (F)Western blotting was performed for H1299 cells after lentiviral infection to detect DHX33 knockdown efficiency. (G) A group
of 5nudemicewere injected in their flanks onone sidewithH1299 cells transducedwith either shSCRor shDHX33 (107 cells per injection). Tumorswere dissected after
6weeks, and imageswere takenbeforeandafter tumorremoval.Tumorweight is labeled in the tumor images. (H)H1299cellswere infectedby lentivirus encodingvector
only, wild-type DHX33, and K94R mutant DHX33. Cells were then plated for soft-agar analysis. Typical images after 14 days of culture incubation are shown. (I) A
Western blot is shown for H1299 cells for overexpression of the indicated proteins. (J) Growth curves were generated over a 6-day period; bars indicate standard
deviations from three separate counts for each sample. vc, vector.
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cer cell lines, equal numbers of these cells were subcutaneously
injected into immunocompromised mice. Six weeks after in-
jection, the control group of immunocompromised mice, in
which we showed that the DHX33 levels were normal, demon-
strated rapid tumor growth while the DHX33 knockdown
group exhibited no detectable tumor, as shown in Fig. 7F and
G. To check the effects of DHX33 overexpression on cancer cell
growth, we overexpressed either a K94R helicase-defective mu-
tant or the wild-type DHX33 in H1299 cells. As shown in Fig. 7H
to J, we found that overexpression of the wild-typeDHX33 caused
an enhancement of anchorage-independent growth and a mild
increase in cell proliferation of H1299 cells. Our results clearly
show that DHX33 is required for lung cancer cell line growth in
vitro and tumor formation in vivo.
DISCUSSION
We report here for the first time that DHX33 binds to the pro-
moter regions of cell cycle genes such as the cyclin A2, cyclin B2,
cyclin E2, MCM4, MCM7, cdc6, cdc20, and E2F1 genes. DHX33
deficiency caused dramatic decreases in the transcription levels of
these genes. We found that DHX33 deficiency caused cell cycle
arrest at G1/S and apoptosis independent of p53. Additionally,
DHX33 physically interacted with these cell cycle gene promot-
ers, recruiting active RNA polymerase II loading onto the pro-
moters of the above-mentioned cell cycle genes. Moreover, by
using the zebrafish model, we found that DHX33 actively reg-
ulates genes involved in the cell cycle in vivo, and this is very
important for embryo development. DHX33 null mutants
showed severe developmental defects in the brain and in the eye;
all homozygous DHX33 mutant embryos died by 7 days postfer-
tilization.
DHX33was found to be overexpressed in Ras-mutated human
lung cancer cell lines and a subset of human lung cancers. This is
consistent with previous findings that DHX33 is a downstream
target of Ras. DHX33was found to be pivotal for proliferation and
growth both in vitro and in vivo. DHX33 was found to be a critical
transcriptional regulator of cell cycle control genes. Acute knock-
down of DHX33 caused apoptosis in lung cancer cells but not in
immortalized normal lung epithelial cells. We previously ob-
served that in wild-typemouse embryonic fibroblasts (MEFs) and
human primary fibroblasts, the majority of cells were arrested in
G1/S-phase transition after DHX33 depletion (3, 7) and that this
was dependent on p53 function. Our study with lung cancer cells
indicates that DHX33 deficiency causes cell cycle arrest or apop-
tosis independent of p53.We have previously foundDHX33 to be
a protein capable of associating with chromatin (3). In this study,
we performed ChIP assays/EMSAs and found that DHX33 readily
interacted with promoters of numerous important cell cycle-reg-
ulatory genes, whose transcriptional upregulation has been re-
ported in human cancers. It would be worthwhile to perform a
global ChIP sequencing analysis for DHX33 protein in different
cell types and tissues to determine the global extent to which
DHX33 directly influences transcription. Further in-depth ChIP
sequencing should be able to identify the specific regions of gene
promoters that DHX33 binds to. This is not the first time that
DEAD/DEAH box proteins have been found to regulate gene
transcription. Recently, a study showed that DDX21 binds 7SK
RNA and is recruited to the promoters of Pol II-transcribed genes
encoding ribosomal proteins and snoRNAs (21). Our results fur-
ther strengthen the concept that DEAD/DEAH box proteins can-
not only influence RNA metabolism but also shape DNA tran-
scription.
Our report on DHX33 underscores its importance as a drug-
gable target in treating Ras-mutated lung cancer patients. Muta-
tion of Ras occurs frequently in not only lung cancers but also a
variety of other types of cancers. Successfully targeting Ras has
proven difficult in the clinic (22, 23). Given the difficulty in de-
signing potent clinical inhibitors for Ras, key downstream effec-
tors of Ras might provide alternative, promising therapeutic tar-
gets for the treatment of Ras-mutated cancers (24).Our study here
demonstrates that DHX33 is an important factor downstream of
Ras for tumor formation. By inhibiting DHX33 through the in-
troduction of small interfering RNAs, Ras-mutated human cancer
cells lost their tumorigenicity and rapidly succumbed to apopto-
sis. Therefore, our findings offer DHX33 as a possible target for
the future treatment of Ras-mutated human cancers. However,
given the essential role of DHX33 in normal cell proliferation,
excessive use of inhibitors for this proteinmay have a potential for
toxicity to normal tissues.
The family of DEAD/DEAH box RNA helicases belongs to a
large family of multifunctional proteins involved in various steps
of RNAmetabolism (25).Many characterized RNA helicases have
been found to be fundamental in essential cellular processes (1,
26). In recent years, a few RNA helicases have been found to par-
ticipate in cancer development even though their detailed molec-
ular mechanisms remain largely undiscovered (27–33). Further-
more, despite the characterization of several DEAD/DEAH
proteins, few specific inhibitors targeting these ATP-dependent
helicases have been developed. Several lines of evidence from ear-
lier studies demonstrate that RNA helicase inhibitors are promis-
ing cancer drugs for the future (34, 35). Clearly, the diversity of
DEAD/DEAH helicases in promoting cancer development war-
rants a broader evaluation of this protein family and the rational
design of their inhibitors. Our study here demonstrates the im-
portance ofDHX33 in cell cycle transcriptional control and tumor
development.
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